Victor S. C. Wong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Victor S. C. Wong has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Patricia Lee Brubaker
University of Toronto
4 shared publications - Dianna E. Willis
Burke Neurological Institute White Plains New York USA
3 shared publications I George Fantus
Department of Medicine, Division of Endocrinology and Metabolism and the Department of Physiology, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsKristine Uffelman
Department of Medicine, Division of Endocrinology and Metabolism and the Department of Physiology, University of Toronto, Toronto, Ontario, Canada
2 shared publicationsLinda Szeto
Department of Medicine, Division of Endocrinology and Metabolism and the Department of Physiology, University of Toronto, Toronto, Ontario, Canada
2 shared publications- Marie-Christine Chaboissier
Université Côte d'Azur, CNRS, INSERM, iBV
2 shared publications
Latest Publications
- 1 June 2020
- Published by Elsevier in Experimental Neurology
- Vol. 328, 113281
HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice
- 1 June 2020
- Published by Elsevier in Experimental Neurology
- Vol. 328, 113281
HDAC6 inhibition promotes α-tubulin acetylation and ameliorates CMT2A peripheral neuropathy in mice
- 31 January 2019
- Published by Wiley in European Journal of Neuroscience
- Vol. 50 (1) , 1741-1758
Semaphorin 3A induces acute changes in membrane excitability in spiral ganglion neurons in vitro
The development and survival of spiral ganglion neurons (SGNs) are dependent on multiple trophic factors as well as membrane electrical activity. Semaphorins (Sema) constitute a family of membrane‐associated and secreted proteins that have garnered significant attention as a potential SGN “navigator” during cochlea development. Previous studies using mutant mice demonstrated that Sema3A plays a role in the SGN pathfinding. The mechanisms, however, by which Sema3A shapes SGNs firing behavior are not known. In these studies, we found that Sema3A plays a novel role in regulating SGN resting membrane potential and excitability. Using dissociated SGN from pre‐hearing (P3–P5) and post‐hearing mice (P12–P15), we recorded membrane potentials using whole‐cell patch clamp recording techniques in apical and basal SGN populations. Recombinant Sema3A was applied to examine the effects on intrinsic membrane properties and action potentials evoked by current injections. Apical and basal SGNs from newborn mice treated with recombinant Sema3A (100 ng/ml) displayed a higher resting membrane potential, higher threshold, decreased amplitude, and prolonged latency and duration of spikes. Although a similar phenomenon was observed in SGNs from post‐hearing mice, the resting membrane potential was essentially indistinguishable before and after Sema3A exposure. Sema3A‐mediated changes in membrane excitability were associated with a significant decrease in K+ and Ca2+ currents. Sema3A acts through linopirdine‐sensitive K+ channels in apical, but not in the basal SGNs. Therefore, Sema3A induces differential effects in SGN membrane excitability that are dependent on age and location, and constitutes an additional early and novel effect of Sema3A SGNs in vitro.
- 31 January 2019
- Published by Wiley in European Journal of Neuroscience
- Vol. 50 (1) , 1741-1758
Semaphorin 3A induces acute changes in membrane excitability in spiral ganglion neurons in vitro
The development and survival of spiral ganglion neurons (SGNs) are dependent on multiple trophic factors as well as membrane electrical activity. Semaphorins (Sema) constitute a family of membrane‐associated and secreted proteins that have garnered significant attention as a potential SGN “navigator” during cochlea development. Previous studies using mutant mice demonstrated that Sema3A plays a role in the SGN pathfinding. The mechanisms, however, by which Sema3A shapes SGNs firing behavior are not known. In these studies, we found that Sema3A plays a novel role in regulating SGN resting membrane potential and excitability. Using dissociated SGN from pre‐hearing (P3–P5) and post‐hearing mice (P12–P15), we recorded membrane potentials using whole‐cell patch clamp recording techniques in apical and basal SGN populations. Recombinant Sema3A was applied to examine the effects on intrinsic membrane properties and action potentials evoked by current injections. Apical and basal SGNs from newborn mice treated with recombinant Sema3A (100 ng/ml) displayed a higher resting membrane potential, higher threshold, decreased amplitude, and prolonged latency and duration of spikes. Although a similar phenomenon was observed in SGNs from post‐hearing mice, the resting membrane potential was essentially indistinguishable before and after Sema3A exposure. Sema3A‐mediated changes in membrane excitability were associated with a significant decrease in K+ and Ca2+ currents. Sema3A acts through linopirdine‐sensitive K+ channels in apical, but not in the basal SGNs. Therefore, Sema3A induces differential effects in SGN membrane excitability that are dependent on age and location, and constitutes an additional early and novel effect of Sema3A SGNs in vitro.
- Open Access
- 31 January 2019
- Published by Society for Neuroscience in eneuro
- Vol. 6 (1)
Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors
Ferroptotic death is a mechanism for tumor suppression by pharmacological inhibitors that target the Xc−transporter (cystine/glutamate antiporter) in a host of non-CNS and CNS tumors. Inhibition of this transporter leads to reduction of cystine uptake, cyst(e)ine deprivation, subsequent depletion of the versatile antioxidant glutathione, and reactive lipid species-dependent death. Accordingly, pharmacological inhibitors of the Xc−transporter can also induce neuronal cell death raising concerns about toxicity in the CNS and PNS if these agents are used for chemotherapy. Here, we show that ferroptotic death induced by the canonical ferroptosis inducer erastin is similar in HT1080 fibrosarcoma cells and primary cortical neurons although cell death is mediated more potently in cancer cells. Reducing the toxicity of ferroptosis inducers will require, among other things, the identification of agents that protect neurons from ferroptosis but exacerbate it in tumor cells. Although we show that a number of agents known to block ferroptosis in primary mouse neurons also inhibit ferroptosis in fibrosarcoma cells, class I histone deacetylase (HDAC) inhibitors selectively protect neurons while augmenting ferroptosis in cancer cells. Our results further suggest that cell death pathways induced by erastin in these two cell types are statistically identical to each other and identical to oxidative glutamate toxicity in neurons, where death is also mediated via inhibition of Xc−cystine transport. Together, these studies identify HDACs inhibitors as a novel class of agents to augment tumor suppression by ferroptosis induction and to minimize neuronal toxicity that could manifest as peripheral neuropathy or chemo brain.
- 31 January 2019
- Published by Society for Neuroscience in eneuro
- Vol. 6 (1)
Open AccessFerroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors
Ferroptotic death is a mechanism for tumor suppression by pharmacological inhibitors that target the Xc−transporter (cystine/glutamate antiporter) in a host of non-CNS and CNS tumors. Inhibition of this transporter leads to reduction of cystine uptake, cyst(e)ine deprivation, subsequent depletion of the versatile antioxidant glutathione, and reactive lipid species-dependent death. Accordingly, pharmacological inhibitors of the Xc−transporter can also induce neuronal cell death raising concerns about toxicity in the CNS and PNS if these agents are used for chemotherapy. Here, we show that ferroptotic death induced by the canonical ferroptosis inducer erastin is similar in HT1080 fibrosarcoma cells and primary cortical neurons although cell death is mediated more potently in cancer cells. Reducing the toxicity of ferroptosis inducers will require, among other things, the identification of agents that protect neurons from ferroptosis but exacerbate it in tumor cells. Although we show that a number of agents known to block ferroptosis in primary mouse neurons also inhibit ferroptosis in fibrosarcoma cells, class I histone deacetylase (HDAC) inhibitors selectively protect neurons while augmenting ferroptosis in cancer cells. Our results further suggest that cell death pathways induced by erastin in these two cell types are statistically identical to each other and identical to oxidative glutamate toxicity in neurons, where death is also mediated via inhibition of Xc−cystine transport. Together, these studies identify HDACs inhibitors as a novel class of agents to augment tumor suppression by ferroptosis induction and to minimize neuronal toxicity that could manifest as peripheral neuropathy or chemo brain.
- Open Access
- 1 January 2018
- Published by Society for Neuroscience in eneuro
- Vol. 5 (1)
α-Tubulin Acetyltransferase Is a Novel Target Mediating Neurite Growth Inhibitory Effects of Chondroitin Sulfate Proteoglycans and Myelin-Associated Glycoprotein
Damage to the central nervous system (CNS) results in neuronal and axonal degeneration, and subsequent neurological dysfunction. Endogenous repair in the CNS is impeded by inhibitory chemical and physical barriers, such as chondroitin sulfate proteoglycans (CSPGs) and myelin-associated glycoprotein (MAG), which prevent axon regeneration. Previously, it has been demonstrated that the inhibition of axonal histone deacetylase-6 (HDAC6) can promote microtubule α-tubulin acetylation and restore the growth of CSPGs- and MAG-inhibited axons. Since the acetylation of α-tubulin is regulated by two opposing enzymes, HDAC6 (deacetylation) and αTAT1 (acetylation), we have investigated the regulation of these enzymes downstream of a growth inhibitory signal. Our findings show that exposure of primary mouse cortical neurons to soluble CSPGs and MAG substrates cause an acute and RhoA-kinase-dependent reduction in α-tubulin acetylation and αTAT1 protein levels, without changes to either HDAC6 levels or HDAC6 activity. The CSPGs- and MAG-induced reduction in αTAT1 occurs primarily in the distal and middle regions of neurites and reconstitution of αTAT1, either by ROCK inhibition or lentiviral-mediated αTAT1 overexpression, can restore neurite growth. Lastly, we demonstrate that CSPGs and MAG signaling decreases αTAT1 levels post-transcriptionally via a ROCK-dependent increase in αTAT1 protein turnover. Together, these findings define αTAT1 as a novel potential therapeutic target for ameliorating CNS injury characterized by growth inhibitory substrates that are prohibitive to axonal regeneration. Significant Statement Chondroitin sulfate proteoglycans (CSPGs) and myelin-associated glycoprotein (MAG) represent significant barriers to axon regeneration after central nervous system (CNS) injury. Inhibition of axonal histone deacetylase-6 (HDAC6), an enzyme that regulates α-tubulin deacetylation, has been shown to overcome the inhibitory effects of CSPGs and MAG to axon growth. In the present study, we report that αTAT1, the α-tubulin acetyltransferase that opposes HDAC6’s activity, is downregulated in neurites by CSPGs and MAG in cortical neurons, in vitro. This reduction is associated with a loss of α-tubulin acetylation and occurs via a RhoA-kinase-dependent pathway. Restoring αTAT1 expression in CSPGs- or MAG-inhibited cortical neurons rescues neurite growth. Our results suggest that αTAT1 is a potential therapeutic target to promote axonal regeneration in the CNS.
- 1 January 2018
- Published by Society for Neuroscience in eneuro
- Vol. 5 (1)
Open Accessα-Tubulin Acetyltransferase Is a Novel Target Mediating Neurite Growth Inhibitory Effects of Chondroitin Sulfate Proteoglycans and Myelin-Associated Glycoprotein
Damage to the central nervous system (CNS) results in neuronal and axonal degeneration, and subsequent neurological dysfunction. Endogenous repair in the CNS is impeded by inhibitory chemical and physical barriers, such as chondroitin sulfate proteoglycans (CSPGs) and myelin-associated glycoprotein (MAG), which prevent axon regeneration. Previously, it has been demonstrated that the inhibition of axonal histone deacetylase-6 (HDAC6) can promote microtubule α-tubulin acetylation and restore the growth of CSPGs- and MAG-inhibited axons. Since the acetylation of α-tubulin is regulated by two opposing enzymes, HDAC6 (deacetylation) and αTAT1 (acetylation), we have investigated the regulation of these enzymes downstream of a growth inhibitory signal. Our findings show that exposure of primary mouse cortical neurons to soluble CSPGs and MAG substrates cause an acute and RhoA-kinase-dependent reduction in α-tubulin acetylation and αTAT1 protein levels, without changes to either HDAC6 levels or HDAC6 activity. The CSPGs- and MAG-induced reduction in αTAT1 occurs primarily in the distal and middle regions of neurites and reconstitution of αTAT1, either by ROCK inhibition or lentiviral-mediated αTAT1 overexpression, can restore neurite growth. Lastly, we demonstrate that CSPGs and MAG signaling decreases αTAT1 levels post-transcriptionally via a ROCK-dependent increase in αTAT1 protein turnover. Together, these findings define αTAT1 as a novel potential therapeutic target for ameliorating CNS injury characterized by growth inhibitory substrates that are prohibitive to axonal regeneration. Significant Statement Chondroitin sulfate proteoglycans (CSPGs) and myelin-associated glycoprotein (MAG) represent significant barriers to axon regeneration after central nervous system (CNS) injury. Inhibition of axonal histone deacetylase-6 (HDAC6), an enzyme that regulates α-tubulin deacetylation, has been shown to overcome the inhibitory effects of CSPGs and MAG to axon growth. In the present study, we report that αTAT1, the α-tubulin acetyltransferase that opposes HDAC6’s activity, is downregulated in neurites by CSPGs and MAG in cortical neurons, in vitro. This reduction is associated with a loss of α-tubulin acetylation and occurs via a RhoA-kinase-dependent pathway. Restoring αTAT1 expression in CSPGs- or MAG-inhibited cortical neurons rescues neurite growth. Our results suggest that αTAT1 is a potential therapeutic target to promote axonal regeneration in the CNS.
- 28 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6336) , 386-387
Community network for deaf scientists
- 28 April 2017
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6336) , 386-387
Community network for deaf scientists
- 1 June 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 625, 26-33
Epigenetic changes following traumatic brain injury and their implications for outcome, recovery and therapy
- 1 June 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 625, 26-33
Epigenetic changes following traumatic brain injury and their implications for outcome, recovery and therapy
- Open Access
- 1 June 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (24) , 16802-16813
Functional Significance of K+ Channel β-Subunit KCNE3 in Auditory Neurons
- 1 June 2014
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 289 (24) , 16802-16813
Open AccessFunctional Significance of K+ Channel β-Subunit KCNE3 in Auditory Neurons
- 1 January 2014
- Published by Wolters Kluwer Health in Pancreas
- Vol. 43 (1) , 93-102
R-spondin1 Deficiency Enhances β-Cell Neogenesis in a Murine Model of Diabetes
Objective The cWnt activator, R-spondin1 (Rspo1), regulates β-cell growth, function, and neogenesis, although its role in conditions such as streptozotocin (STZ)-induced diabetes is unknown. We hypothesized that Rspo1 deficiency enhances β-cell neogenesis in STZ-induced diabetes. Methods Wild-type (Rspo1+/+) and knockout (Rspo1−/−) mice were injected with STZ (40 mg/kg) for 5 days, followed by analysis of oral glucose and insulin tolerance, and were killed on day 6 (acute; 9–11 mice) or 32 (chronic; 11–16 mice). Immunohistochemistry was performed for β-cell apoptosis, proliferation, neogenesis, and markers of β-cell maturity. Results There was no difference in oral glucose handling between STZ-induced Rspo1+/+ and Rspo1−/− mice, although Rspo1−/− mice demonstrated increased insulin sensitivity. β-cell mass, islet number, and islet size distribution did not differ between STZ-induced Rspo1+/+ and Rspo1−/− mice, but Rspo1−/− animals had reduced β-cell apoptosis and increased numbers of insulin-positive ductal cells, indicating β-cell neogenesis. Furthermore, the increased β-cell regeneration observed in the Rspo1−/− animals was associated with a more differentiated/mature β-cell phenotype as assessed by increased immunopositivity for Nkx6.1, MafA, and GLUT2. Conclusions These findings indicate that Rspo1 is a negative regulator of β-cell neogenesis, development, and survival in the face of STZ-induced diabetes, providing a therapeutic target for the enhancement of β-cell mass.
- 1 January 2014
- Published by Wolters Kluwer Health in Pancreas
- Vol. 43 (1) , 93-102
R-spondin1 Deficiency Enhances β-Cell Neogenesis in a Murine Model of Diabetes
Objective The cWnt activator, R-spondin1 (Rspo1), regulates β-cell growth, function, and neogenesis, although its role in conditions such as streptozotocin (STZ)-induced diabetes is unknown. We hypothesized that Rspo1 deficiency enhances β-cell neogenesis in STZ-induced diabetes. Methods Wild-type (Rspo1+/+) and knockout (Rspo1−/−) mice were injected with STZ (40 mg/kg) for 5 days, followed by analysis of oral glucose and insulin tolerance, and were killed on day 6 (acute; 9–11 mice) or 32 (chronic; 11–16 mice). Immunohistochemistry was performed for β-cell apoptosis, proliferation, neogenesis, and markers of β-cell maturity. Results There was no difference in oral glucose handling between STZ-induced Rspo1+/+ and Rspo1−/− mice, although Rspo1−/− mice demonstrated increased insulin sensitivity. β-cell mass, islet number, and islet size distribution did not differ between STZ-induced Rspo1+/+ and Rspo1−/− mice, but Rspo1−/− animals had reduced β-cell apoptosis and increased numbers of insulin-positive ductal cells, indicating β-cell neogenesis. Furthermore, the increased β-cell regeneration observed in the Rspo1−/− animals was associated with a more differentiated/mature β-cell phenotype as assessed by increased immunopositivity for Nkx6.1, MafA, and GLUT2. Conclusions These findings indicate that Rspo1 is a negative regulator of β-cell neogenesis, development, and survival in the face of STZ-induced diabetes, providing a therapeutic target for the enhancement of β-cell mass.
- 12 April 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (7) , 1726-1734
R-spondin1 deficiency in mice improves glycaemic control in association with increased beta cell mass
Aims/hypothesis Roof plate-specific spondin (R-spondin1; RSPO1) is a modulator of canonical Wg (wingless) plus Int1 (chromosomal integration site of mouse mammary tumour virus on mouse chromosome 15) (cWNT) signalling that induces cWNT target genes. We have demonstrated that Rspo1 is expressed in murine beta cells, and that it stimulates proliferation and insulin secretion, and inhibits cytokine-induced apoptosis, in mouse insulinoma (MIN6) and beta cells. We thus investigated the role of RSPO1 in beta cells in vivo using Rspo1 −/− mice. Methods The effects of Rspo1 deficiency were assessed by determination of cWNT signalling, glucose tolerance and beta cell mass. Results Rspo1 −/− mice demonstrated an 82% reduction in RSPO1 transcripts and a 61% reduction in the signal detected by an RSPO1 antibody, as well as a 47% decrease in islet cWNT signalling. Despite no differences in body and pancreatic weights or in fasting glycaemia and insulinaemia compared with Rspo1 +/+ mice, Rspo1 −/− animals had improved glycaemic control after oral glucose challenge (p < 0.05), with no difference in insulin sensitivity, but an enhanced insulin response over 30 min (p < 0.05); glucagon responses were normal. Rspo1 deficiency also resulted in a twofold increase in beta cell mass (p < 0.05) in association with 2- and 12-fold increases in the number of beta cells positive for antigen identified by monoclonal antibody Ki67 (Ki67) (p < 0.01) and insulin-positive ductal cells (p < 0.05), respectively. No change in the number of TUNEL-positive beta cells was detected. Islets isolated from Rspo1 −/− animals displayed no differences in glucose-induced insulin secretion or in glucose suppression of glucagon. Conclusions/interpretation The present study reveals an unexpected role for RSPO1 as a regulator of both beta cell proliferation and neogenesis in vivo, and reinforces the importance of cWNT signalling for the maintenance of normal pancreatic beta cell behaviour.
- 12 April 2011
- Published by Springer Nature in Diabetologia
- Vol. 54 (7) , 1726-1734
R-spondin1 deficiency in mice improves glycaemic control in association with increased beta cell mass
Aims/hypothesis Roof plate-specific spondin (R-spondin1; RSPO1) is a modulator of canonical Wg (wingless) plus Int1 (chromosomal integration site of mouse mammary tumour virus on mouse chromosome 15) (cWNT) signalling that induces cWNT target genes. We have demonstrated that Rspo1 is expressed in murine beta cells, and that it stimulates proliferation and insulin secretion, and inhibits cytokine-induced apoptosis, in mouse insulinoma (MIN6) and beta cells. We thus investigated the role of RSPO1 in beta cells in vivo using Rspo1 −/− mice. Methods The effects of Rspo1 deficiency were assessed by determination of cWNT signalling, glucose tolerance and beta cell mass. Results Rspo1 −/− mice demonstrated an 82% reduction in RSPO1 transcripts and a 61% reduction in the signal detected by an RSPO1 antibody, as well as a 47% decrease in islet cWNT signalling. Despite no differences in body and pancreatic weights or in fasting glycaemia and insulinaemia compared with Rspo1 +/+ mice, Rspo1 −/− animals had improved glycaemic control after oral glucose challenge (p < 0.05), with no difference in insulin sensitivity, but an enhanced insulin response over 30 min (p < 0.05); glucagon responses were normal. Rspo1 deficiency also resulted in a twofold increase in beta cell mass (p < 0.05) in association with 2- and 12-fold increases in the number of beta cells positive for antigen identified by monoclonal antibody Ki67 (Ki67) (p < 0.01) and insulin-positive ductal cells (p < 0.05), respectively. No change in the number of TUNEL-positive beta cells was detected. Islets isolated from Rspo1 −/− animals displayed no differences in glucose-induced insulin secretion or in glucose suppression of glucagon. Conclusions/interpretation The present study reveals an unexpected role for RSPO1 as a regulator of both beta cell proliferation and neogenesis in vivo, and reinforces the importance of cWNT signalling for the maintenance of normal pancreatic beta cell behaviour.
- Open Access
- 1 July 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (28) , 21292-21302
R-spondin-1 Is a Novel β-Cell Growth Factor and Insulin Secretagogue
- 1 July 2010
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 285 (28) , 21292-21302
Open AccessR-spondin-1 Is a Novel β-Cell Growth Factor and Insulin Secretagogue